Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2019-10-02
2020-09-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT
NCT03123406
Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis
NCT05926570
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
NCT01071070
DePTH: De-emphasize PTH
NCT06288451
Parathyroid Hyperplasia in Patients With Chronic Kidney Disease.
NCT03182517
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
XBDP1-
Nifedipine controlled released tablets
lower blood pressure
XBDP2-
Nifedipine controlled released tablets
lower blood pressure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nifedipine controlled released tablets
lower blood pressure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The clinical physician diagnosed CKD with hypertension;
* The physician decided that nifedipine controlled release tablets should be given.
* Subjects agree to the study protocol, clinical and follow-up time, and sign the informed consent after the approval of the ethics committee;
* Subjects will be able to communicate well with the investigator and will be able to complete the study as required.
Exclusion Criteria
* Other clinical reasons that may be considered inappropriate for inclusion by clinicians.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Third Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yang GuoPing, doctor
Role: PRINCIPAL_INVESTIGATOR
The Third Xiangya Hospital of Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Third Xiangya Hospital of Central South University , , China,
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XY3-PTH1708A01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.